Design Therapeutics, Inc.
Design Therapeutics, Inc. (Nasdaq: DSGN) is a clinical-stage biopharmaceutical company developing GeneTAC® small-molecule therapeutics for inherited diseases caused by nucleotide repeat expansions. Its platform is designed to target expanded genetic sequences and modulate gene expression to address either deficient… From the company’s description.
In fiscal 2025, Design Therapeutics, Inc. reported a net loss of $69.79M. Operations used $54.36M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Design Therapeutics, Inc. does
In the company’s own words
Design Therapeutics, Inc. (Nasdaq: DSGN) is a clinical-stage biopharmaceutical company developing GeneTAC® small-molecule therapeutics for inherited diseases caused by nucleotide repeat expansions. Its platform is designed to target expanded genetic sequences and modulate gene expression to address either deficient proteins or toxic gene products. The company’s programs include DT-216P2 for Friedreich ataxia and DT-168 for Fuchs endothelial corneal dystrophy, both in clinical development; DT-818 for myotonic dystrophy type 1, cleared to begin clinical development; and preclinical candidates for Huntington’s disease and other conditions. GeneTAC® is the company’s principal technology and product platform, and its development candidates are intended to address disease mechanisms at the genetic level. The company focuses on patients with inherited repeat-expansion diseases and does not report separate business segments. Its website is www.designtx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CARLSBAD, CA
- Fiscal year end
- December
- CIK
- 1807120
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Design Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Design Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Design Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Design Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Design Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”